AUTHORS
Nooshin Tabatabaei-Zavareh, (PhD, MD), Tim A Le Fevre, BSc2, Iulia M Oros3, Elaine Ang4, Brandon M Wong5, Jessica M Hitchon6, Manish P Sadalapure7, Allen C Eaves, MD, PhD8, Sharon A Louis, PhD9
AFFILIATIONS
1 STEMCELL Technologies, Vancouver, British Columbia, Canada
2 STEMCELL Technologies, Vancouver, British Columbia, Canada
3 STEMCELL Technologies, Vancouver, British Columbia, Canada
4 STEMCELL Technologies, Vancouver, British Columbia, Canada
5 STEMCELL Technologies, Vancouver, British Columbia, Canada
6 STEMCELL Technologies, Vancouver, British Columbia, Canada
7 STEMCELL Technologies, Vancouver, British Columbia, Canada
8 BC Cancer Research Centre, Vancouver, British Columbia, Canada, STEMCELL Technologies, Vancouver, British Columbia, Canada
9 STEMCELL Technologies, Vancouver, British Columbia, Canada
ABSTRACT
T and natural killer (NK) cells are promising cell therapeutic products for various malignancies due to their capacity to destroy cancerous cells and modulate immune responses through cytokine secretion. However, the complex manufacturing and high cost of autologous cell therapies limit access to these critical therapies. Human pluripotent stem cells (hPSCs) hold great potential for improving the accessibility problem by enabling the production of large quantities of “off-the-shelf” allogeneic T and NK cells for use in cell therapy. hPSC differentiation to T and NK cells is a multi-step process requiring transition through a hematopoietic stem and/or progenitor cell (HSPC) stage and lymphoid progenitor (LP) cell stage. Achieving consistent cell manufacturing depends on the availability of high-quality, cGMP-compliant ancillary materials and reagents that support robust differentiation processes. To address this challenge, we developed an optimized, cGMP-compliant, animal component- and serum-free Lymphoid Differentiation Supplement (LDS) to support HSPC differentiation into T and NK cells for pre-clinical development and cell manufacturing.
To evaluate this novel cGMP supplement, CD34+ hPSC-derived HSPCs were generated using commercially-available STEMdiff Hematopoietic EB reagents and a scalable suspension culture protocol. Fresh or cryopreserved CD34+ cells were cultured in cGMP HSPC medium supplemented with LDS on plates prepared with Lymphoid Differentiation Coating Material for 7 - 14 days to obtain an intermediate CD5+CD7+ LP cell population. LP cells were then further cultured under T or NK cell-specific differentiation conditions for 14 - 28 days to generate CD4+CD8+ double-positive (DP) T cells or CD56+ NK cells, respectively. DP T cells were matured to CD8+ single-positive (SP) T cells after the extension of culture with T cell stimulation and IL-15. Both CD8+ SP T cells and CD56+ NK cells were then functionally assessed using a flow cytometry-based cytotoxicity assay.
hPSC-derived CD34+ HSPCs cultured with LDS generated an average frequency of 42 ± 2% CD5+CD7+ LP cells with a yield of 455 ± 74 per input PSC (n = 1 - 10, 8 cell lines). These LP cells were then differentiated into CD4+CD8+ DP T cells with an average frequency of 33 ± 3% and a yield of 204 ± 62 per input PSC (n = 1 - 9, 8 cell lines) and further matured to CD8+ SP T cells after an additional week of culture. For NK cell differentiation, hPSC-derived LP cells generated with LDS produced 81 ± 2% CD56+ cells, with a yield of 13861 ± 3906 per input PSC (n = 1 - 6, 8 cell lines). The resulting CD8+ SP T cells and CD56+ NK cells were functional and able to kill NALM6 and K562 target cells, respectively.
Taken together, our data show that this novel cGMP-compliant Lymphoid Differentiation Supplement enables efficient and robust differentiation of hPSC-derived CD34+ HSPCs and generation of CD5+CD7+ lymphoid progenitor cells, which can then be differentiated to functional CD8+ SP T cells and CD56+ NK cells. By generating clinically relevant numbers of lymphoid progenitor cells from multiple hPSC sources, this cGMP supplement sets the stage for robust and scalable manufacturing of functional allogenetic T and NK cells for translational research.
DISCLOSURES
Nooshin Tabatabaei-Zavareh, (PhD, MD): STEMCELL Technologies - Current Employment